Status:

COMPLETED

Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus

Lead Sponsor:

Indiana University

Collaborating Sponsors:

Juvenile Diabetes Research Foundation

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

12-55 years

Brief Summary

Despite the valuable information derived from older studies evaluating type 1 diabetes, the diabetes research community has, in large part, overlooked potential contributions of baseline abnormalities...

Eligibility Criteria

Inclusion

  • Inclusion criteria for each subject group\* note age limits different for each group\*:
  • Nonrelative controls: Male and female adults 18-55 years old with no family history of Type 1 Diabetes, who have tested negative for glutamic acid decarboxylase, microinsulin, islet cell, islet antigen 2, and zinc transporter 8 autoantibodies
  • Ab negative FDRs: Male and female adults 18-50 years old with a first degree relative (sibling, child, or parent) with T1D, who have tested negative for the above islet autoantibodies
  • Ab + T1D Relatives: Male and females aged 12-50 years old with a first or second degree relative diagnosed with T1D, and testing positive for 1 of the above islet autoantibodies either at the screening visit, or through TrialNet screening obtained within the past 12 months.
  • Criteria for all subjects:
  • BMI≤40 kg/m2 (If FDR is 40 kg/m2, the healthy control BMI can not exceed 45 kg/m2)
  • HbA1c\< 5.7%
  • No medical history of diabetes.
  • Exclusion criteria for all participants:
  • Any type of diabetes or hyperglycemia (HbA1c≥5.7%)
  • Chronic illness or use of medications which interfere with glucose or islet hormone metabolism.
  • Hemoglobin \< 12 g/dL
  • Presence of any psychiatric disorder that will affect the ability to participate in the study
  • Pregnancy
  • Severe milk or soy allergy that would disallow Boost® ingestion for MMTT
  • Any condition that, in the judgment of the investigator, will adversely affect adequate participation in, or the safety or technical performance of the protocol.

Exclusion

    Key Trial Info

    Start Date :

    November 14 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 27 2021

    Estimated Enrollment :

    70 Patients enrolled

    Trial Details

    Trial ID

    NCT04362917

    Start Date

    November 14 2017

    End Date

    August 27 2021

    Last Update

    March 16 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Indiana University

    Indianapolis, Indiana, United States, 46202